Eikon reports Q3 2026 results, ESMO oncology data and new prostate cancer INDNov 12Quarterly updateAkari Therapeutics PlcAtrium Therapeutics
Candel Therapeutics adds Martine Zimmermann to board ahead of planned BLA filingSep 10Peopleaglatimagene besadenovecCandel Therapeutics, Inc.
Candel targets Q4 2026 BLA for prostate cancer therapy, opens NSCLC phase 3 trialAug 13Quarterly updateCandel Therapeutics, Inc.